Zardaverine | CAS#101975-10-4 | Phosphodiesterase 3/4 inhibitor

MedKoo Cat#: 326721 | Name: Zardaverine

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Zardaverine is a Phosphodiesterase 3/4 inhibitor. Zardaverine exhibits potent and selective antitumor activity against hepatocellular carcinoma both in vitro and in vivo independently of phosphodiesterase inhibition. Zardaverine may be also useful for both, bronchorelaxation and reduction of inflammation in asthma therapy.

Chemical Structure

Zardaverine

CAS#101975-10-4

Theoretical Analysis

MedKoo Cat#: 326721

Name: Zardaverine

CAS#: 101975-10-4

Chemical Formula: C12H10F2N2O3

Exact Mass: 268.0659

Molecular Weight: 268.22

Elemental Analysis: C, 53.74; H, 3.76; F, 14.17; N, 10.44; O, 17.89

Price and Availability

Size	Price	Availability	Quantity
5mg	USD 200.00
10mg	USD 350.00
25mg	USD 750.00

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

Zardaverine

IUPAC/Chemical Name

6-(4-(Difluoromethoxy)-3-methoxyphenyl)-3(2H)-pyridazinone

InChi Key

HJMQDJPMQIHLPB-UHFFFAOYSA-N

InChi Code

InChI=1S/C12H10F2N2O3/c1-18-10-6-7(2-4-9(10)19-12(13)14)8-3-5-11(17)16-15-8/h2-6,12H,1H3,(H,16,17)

SMILES Code

O=C1C=CC(C2=CC=C(OC(F)F)C(OC)=C2)=NN1

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 268.22 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Kȩdzierski J, van Diest RE, Allard JA, Odermatt A, Smieško M. Discovery of non-steroidal aldo-keto reductase 1D1 inhibitors through automated screening and in vitro evaluation. Toxicol Lett. 2025 Feb 21;406:31-37. doi: 10.1016/j.toxlet.2025.02.009. Epub ahead of print. PMID: 39988211. 2: Tong L, Shan M, Zou W, Liu X, Felsher DW, Wang J. Cyclic adenosine monophosphate/phosphodiesterase 4 pathway associated with immune infiltration and PD-L1 expression in lung adenocarcinoma cells. Front Oncol. 2022 Aug 1;12:904969. doi: 10.3389/fonc.2022.904969. PMID: 35978822; PMCID: PMC9376450. 3: Moniot A, Braux J, Siboni R, Guillaume C, Audonnet S, Allart-Simon I, Sapi J, Tirouvanziam R, Gérard S, Gangloff SC, Velard F. Inhibition of Recruitment and Activation of Neutrophils by Pyridazinone-Scaffold-Based Compounds. Int J Mol Sci. 2022 Jun 29;23(13):7226. doi: 10.3390/ijms23137226. PMID: 35806233; PMCID: PMC9266889. 4: Rathi A, Kumar V, Sundar D. Insights into the potential of withanolides as Phosphodiesterase-4 (PDE4D) inhibitors. J Biomol Struct Dyn. 2023 Apr;41(6):2108-2117. doi: 10.1080/07391102.2022.2028679. Epub 2022 Jan 21. PMID: 35060432. 5: Schuster KD, Mohammadi M, Cahill KB, Matte SL, Maillet AD, Vashisth H, Cote RH. Pharmacological and molecular dynamics analyses of differences in inhibitor binding to human and nematode PDE4: Implications for management of parasitic nematodes. PLoS One. 2019 Mar 27;14(3):e0214554. doi: 10.1371/journal.pone.0214554. PMID: 30917179; PMCID: PMC6436744. 6: Jeong J, Sa SJ, Chung H, Baek S, Choi I. A Dual Phosphodiesterase Inhibitor, Zardaverine (Type 3/4), Enhances Motility of Frozen-thawed Boar Sperm. Cryo Letters. 2018 May/Jun;39(3):196-200. PMID: 30059566. 7: Nazir M, Senkowski W, Nyberg F, Blom K, Edqvist PH, Jarvius M, Andersson C, Gustafsson MG, Nygren P, Larsson R, Fryknäs M. Targeting tumor cells based on Phosphodiesterase 3A expression. Exp Cell Res. 2017 Dec 15;361(2):308-315. doi: 10.1016/j.yexcr.2017.10.032. Epub 2017 Oct 26. PMID: 29107068. 8: Cartledge DM, Robbins KM, Drake KM, Sternberg R, Stabley DL, Gripp KW, Kolb EA, Sol-Church K, Napper AD. Cytotoxicity of Zardaverine in Embryonal Rhabdomyosarcoma from a Costello Syndrome Patient. Front Oncol. 2017 Apr 3;7:42. doi: 10.3389/fonc.2017.00042. PMID: 28421158; PMCID: PMC5376947. 9: Guariento S, Karawajczyk A, Bull JA, Marchini G, Bielska M, Iwanowa X, Bruno O, Fossa P, Giordanetto F. Design and synthesis of 4,5,6,7-tetrahydro-1H-1,2-diazepin-7-one derivatives as a new series of Phosphodiesterase 4 (PDE4) inhibitors. Bioorg Med Chem Lett. 2017 Jan 1;27(1):24-29. doi: 10.1016/j.bmcl.2016.11.040. Epub 2016 Nov 16. PMID: 27890378. 10: Kel AE, Stegmaier P, Valeev T, Koschmann J, Poroikov V, Kel-Margoulis OV, Wingender E. Multi-omics "upstream analysis" of regulatory genomic regions helps identifying targets against methotrexate resistance of colon cancer. EuPA Open Proteom. 2016 Sep 9;13:1-13. doi: 10.1016/j.euprot.2016.09.002. PMID: 29900117; PMCID: PMC5988513. 11: Rogliani P, Calzetta L, Capuani B, Facciolo F, Cazzola M, Lauro D, Matera MG. Glucagon-Like Peptide 1 Receptor: A Novel Pharmacological Target for Treating Human Bronchial Hyperresponsiveness. Am J Respir Cell Mol Biol. 2016 Dec;55(6):804-814. doi: 10.1165/rcmb.2015-0311OC. PMID: 27447052. 12: Mastrototaro L, Tietjen U, Sponder G, Vormann J, Aschenbach JR, Kolisek M. Insulin Modulates the Na+/Mg2+ Exchanger SLC41A1 and Influences Mg2+ Efflux from Intracellular Stores in Transgenic HEK293 Cells. J Nutr. 2015 Nov;145(11):2440-7. doi: 10.3945/jn.115.213918. Epub 2015 Sep 9. PMID: 26355001. 13: Sun L, Quan H, Xie C, Wang L, Hu Y, Lou L. Phosphodiesterase 3/4 inhibitor zardaverine exhibits potent and selective antitumor activity against hepatocellular carcinoma both in vitro and in vivo independently of phosphodiesterase inhibition. PLoS One. 2014 Mar 5;9(3):e90627. doi: 10.1371/journal.pone.0090627. PMID: 24598942; PMCID: PMC3944092. 14: Kümmerle AE, Schmitt M, Cardozo SV, Lugnier C, Villa P, Lopes AB, Romeiro NC, Justiniano H, Martins MA, Fraga CA, Bourguignon JJ, Barreiro EJ. Design, synthesis, and pharmacological evaluation of N-acylhydrazones and novel conformationally constrained compounds as selective and potent orally active phosphodiesterase-4 inhibitors. J Med Chem. 2012 Sep 13;55(17):7525-45. doi: 10.1021/jm300514y. Epub 2012 Aug 30. PMID: 22891752. 15: Fryknäs M, Rickardson L, Wickström M, Dhar S, Lövborg H, Gullbo J, Nygren P, Gustafsson MG, Isaksson A, Larsson R. Phenotype-based screening of mechanistically annotated compounds in combination with gene expression and pathway analysis identifies candidate drug targets in a human squamous carcinoma cell model. J Biomol Screen. 2006 Aug;11(5):457-68. doi: 10.1177/1087057106288048. PMID: 16928983. 16: Krier M, Araújo-Júnior JX, Schmitt M, Duranton J, Justiano-Basaran H, Lugnier C, Bourguignon JJ, Rognan D. Design of small-sized libraries by combinatorial assembly of linkers and functional groups to a given scaffold: application to the structure-based optimization of a phosphodiesterase 4 inhibitor. J Med Chem. 2005 Jun 2;48(11):3816-22. doi: 10.1021/jm050063y. PMID: 15916433. 17: Fiorini C, Tilloy-Ellul A, Chevalier S, Charuel C, Pointis G. Sertoli cell junctional proteins as early targets for different classes of reproductive toxicants. Reprod Toxicol. 2004 May;18(3):413-21. doi: 10.1016/j.reprotox.2004.01.002. PMID: 15082077. 18: Park H, Clark E, Conklin JL. Effects of phosphodiesterase inhibitors on oesophageal neuromuscular functions. Neurogastroenterol Motil. 2003 Dec;15(6):625-33. doi: 10.1046/j.1350-1925.2003.00444.x. PMID: 14651598. 19: Schermuly RT, Leuchte H, Ghofrani HA, Weissmann N, Rose F, Kohstall M, Olschewski H, Schudt C, Grimminger F, Seeger W, Walmrath D. Zardaverine and aerosolised iloprost in a model of acute respiratory failure. Eur Respir J. 2003 Aug;22(2):342-7. doi: 10.1183/09031936.03.00093802. PMID: 12952271. 20: Lee ME, Markowitz J, Lee JO, Lee H. Crystal structure of phosphodiesterase 4D and inhibitor complex(1). FEBS Lett. 2002 Oct 23;530(1-3):53-8. doi: 10.1016/s0014-5793(02)03396-3. PMID: 12387865.